James Heckmann, MD
Hematology/Oncology · Sunnyvale
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 12
- 3 carriers
- Office
- 1
Offices
1 location · Sutter Bay Medical Foundation · 3,783 clinicians in this group
Plans that list them
12 plans · 3 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Heckmann’s office at (408) 739-6000 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
12 of 12 plans
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Sutter Advantage +More (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| SCAN Strive (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| DualConnect (HMO D-SNP) | Santa Clara Family Health Plan | Listed | Sep 1, 2026 |
California Medical Board record
Licence G29205 · Current
Licensed to practise in California · since 1975 · expires 2027-02-28 · University of Kentucky College of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Original Medicare doctor bills
$524,934
Medicare paid this office $524,934 for 164 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Injection, denosumab, 1 mg | 25 | $34,042 | None |
| Administration of chemotherapy into vein, 1 hour or less | 31 | $8,551 | $140 |
| Long return visit (40+ min) | 15 | $3,972 | $159 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 39 | $3,626 | $67 |
| New patient visit (60+ min) | 15 | $3,116 | $208 |
See all 10 services
| Injection, denosumab, 1 mg | 25 | $34,042 | None |
| Administration of chemotherapy into vein, 1 hour or less | 31 | $8,551 | $140 |
| Long return visit (40+ min) | 15 | $3,972 | $159 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 39 | $3,626 | $67 |
| New patient visit (60+ min) | 15 | $3,116 | $208 |
| Injection of drug or substance under skin or into muscle | 38 | $999 | $14 |
| Injection of additional new drug or substance into vein | 16 | $752 | $16 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 12 | $505 | $34 |
| Injection, zoledronic acid, 1 mg | 18 | $421 | None |
| Infusion, normal saline solution, 250 cc | 65 | $52 | None |
Who their Medicare patients are
164 Original Medicare patients in 2024. Average age 76 · Women 61% · Also on Medicaid 14% · Health risk score 1.69. At or below the middle of the specialty; the typical hematology-oncology clinician is at 2.04.
Conditions among them: High blood pressure 68% · Diabetes 34% · Cancer 32% · Chronic kidney disease 28% · Coronary heart disease 26% · Atrial fibrillation 16% · COPD 15% · Depression 14% · Heart failure 13% · Dementia 10%.
The office billed $1,662,423, Medicare allowed $658,787 and paid $524,934; for 25,793 services of 91 kinds; $497,859 of it was for drugs given in the office and $27,074 for care.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 164 | 25,793 | 76 | 1.69 | $1,662,423 | $524,934 |
| 2023 | 76 | 8,937 | 75 | 1.84 | $506,495 | $143,363 |
| 2022 | 64 | 8,411 | 77 | 1.84 | $346,308 | $114,411 |
| 2021 | 45 | 6,004 | 76 | 1.94 | $237,262 | $91,495 |
| 2020 | 59 | 5,502 | 74 | 2.30 | $229,444 | $73,467 |
| 2019 | 194 | 23,526 | 75 | 1.97 | $1,082,369 | $357,466 |
| 2018 | 97 | 13,252 | 75 | 2.28 | $544,034 | $163,571 |
| 2017 | 252 | 34,615 | 74 | 2.00 | $2,315,692 | $710,515 |
| 2016 | 27 | 1,770 | 71 | 2.33 | $165,238 | $43,744 |
| 2015 | 48 | 6,289 | 73 | 2.05 | $241,282 | $68,060 |
| 2014 | 104 | 15,852 | 74 | 2.00 | $866,075 | $217,285 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 4 services
| Administration of chemotherapy into vein, 1 hour or less | 14 | $2,551 | $142 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 20 | $1,585 | $63 |
| Injection of drug or substance under skin or into muscle | 14 | $310 | $13 |
| Infusion, normal saline solution, 250 cc | 22 | $17 | None |
2022: 3 services
| Administration of chemotherapy into vein, 1 hour or less | 13 | $2,185 | $146 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 13 | $996 | $66 |
| Injection of drug or substance under skin or into muscle | 16 | $394 | $13 |
2020: 2 services
| Return visit (30+ min) | 20 | $4,094 | $95 |
| Administration of chemotherapy into vein, 1 hour or less | 11 | $2,082 | $149 |
2019: 13 services
| Administration of chemotherapy into vein, 1 hour or less | 42 | $7,035 | $150 |
| Short return visit (20+ min) | 38 | $4,416 | $60 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 42 | $3,433 | $75 |
| Return visit (30+ min) | 21 | $2,859 | $102 |
| Administration of chemotherapy into vein, each additional hour | 19 | $940 | $31 |
| Injection of additional new drug or substance into vein | 24 | $703 | $17 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 16 | $612 | $32 |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 11 | $592 | $22 |
| Injection of drug or substance under skin or into muscle | 18 | $495 | $16 |
| Injection, zoledronic acid, 1 mg | 12 | $338 | None |
| Injection, dexamethasone sodium phosphate, 1 mg | 20 | $23 | None |
| Injection, ondansetron hydrochloride, per 1 mg | 17 | $21 | None |
| Injection, diphenhydramine hcl, up to 50 mg | 15 | $10 | None |
2018: 7 services
| Administration of chemotherapy into vein, 1 hour or less | 18 | $3,555 | $137 |
| Short return visit (20+ min) | 27 | $2,945 | $61 |
| Return visit (30+ min) | 17 | $2,676 | $86 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 19 | $2,029 | $72 |
| Injection of additional new drug or substance into vein | 15 | $863 | $18 |
| Injection of drug or substance under skin or into muscle | 18 | $712 | $19 |
| Injection, dexamethasone sodium phosphate, 1 mg | 12 | $18 | None |
2017: 19 services
| Injection, infliximab, excludes biosimilar, 10 mg | 12 | $58,677 | None |
| Administration of chemotherapy into vein, 1 hour or less | 51 | $12,267 | $135 |
| Short return visit (20+ min) | 57 | $6,805 | $61 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 45 | $6,008 | $66 |
| Return visit (30+ min) | 45 | $5,749 | $91 |
| New patient visit (45+ min) | 29 | $3,710 | $128 |
| Injection of drug or substance under skin or into muscle | 42 | $3,006 | $24 |
| New patient visit (60+ min) | 17 | $2,945 | $173 |
| Administration of additional new drug or substance into vein, 1 hour or less | 18 | $2,396 | $63 |
| Injection of additional new drug or substance into vein | 39 | $2,071 | $22 |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 12 | $1,377 | $16 |
| Administration of chemotherapy into vein, each additional hour | 24 | $1,161 | $27 |
| Injection, zoledronic acid, 1 mg | 22 | $1,049 | None |
| Injection of drug or substance into vein | 16 | $885 | $49 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 14 | $644 | $29 |
| Injection, dexamethasone sodium phosphate, 1 mg | 30 | $53 | None |
| Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | 13 | $42 | None |
| Injection, ondansetron hydrochloride, per 1 mg | 24 | $33 | None |
| Injection, diphenhydramine hcl, up to 50 mg | 16 | $13 | None |
2015: 3 services
| Administration of chemotherapy into vein, 1 hour or less | 13 | $1,895 | $146 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 11 | $1,050 | $75 |
| Injection of drug or substance under skin or into muscle | 13 | $371 | $26 |
2014: 8 services
| Injection, immune globulin, (octagam), intravenous, non-lyophilized (e.g., liquid), 500 mg | 11 | $32,515 | None |
| Administration of chemotherapy into vein, 1 hour or less | 25 | $3,972 | $137 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 32 | $3,295 | $70 |
| Injection of drug or substance under skin or into muscle | 31 | $1,345 | $25 |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 16 | $902 | $18 |
| Injection of additional new drug or substance into vein | 15 | $515 | $22 |
| Injection, dexamethasone sodium phosphate, 1 mg | 12 | $13 | None |
| Injection, ondansetron hydrochloride, per 1 mg | 13 | $11 | None |
Drugs they prescribed that Part D paid
$324,753
Pharmacies billed $324,753 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 61) in 2024. At or below the middle of the specialty; the typical hematology-oncology clinician is at 5%.
23 generic and 38 brand-name prescriptions · $324,753 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Jakafi | 17 | $270,328 | $15,902 |
| Hydroxyurea | 14 | $241 | $17 |
Year by year
| 2024 | 61 | 12 | 0% (0) | 62% | $324,753 |
| 2023 | 66 | 11 | 0% (0) | 86% | $519,819 |
| 2022 | 49 | None | 0% (0) | 61% | $340,161 |
| 2021 | 46 | None | 0% (0) | 57% | $162,968 |
| 2020 | 44 | None | 0% (0) | 43% | $172,278 |
| 2019 | 42 | 14 | 0% (0) | None | $14,364 |
| 2018 | 41 | 13 | 0% (0) | None | $31,524 |
| 2017 | 58 | 14 | 0% (0) | 40% | $45,224 |
| 2014 | 19 | None | None | None | $5,708 |
| 2013 | 36 | None | None | None | $6,043 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 2 drugs
| Jakafi | 39 | $496,623 | $12,734 |
| Eliquis | 12 | $15,929 | $1,327 |
2022: 2 drugs
| Jakafi | 22 | $329,785 | $14,990 |
| Hydroxyurea | 15 | $206 | $14 |
2021: 2 drugs
| Jakafi | 12 | $146,727 | $12,227 |
| Hydroxyurea | 19 | $699 | $37 |
2020: 2 drugs
| Jakafi | 11 | $161,261 | $14,660 |
| Hydroxyurea | 13 | $708 | $54 |
2019: 1 drug
| Hydroxyurea | 17 | $719 | $42 |
2018: 1 drug
| Hydroxyurea | 20 | $672 | $34 |
2017: 2 drugs
| Xarelto | 11 | $6,474 | $589 |
| Hydroxyurea | 19 | $400 | $21 |
Money from drug and device companies
$22 in 2025
| 2025 | 1 | 1 | None | $22 |
| 2024 | 2 | 2 | None | $53 |
| 2022 | 1 | 2 | None | $26 |
| 2021 | 1 | 1 | None | $14 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Astellas Pharma US | Xtandi | $22 | 1 payment
|
See the published payment
| Astellas Pharma US | Meals · 2025-07-28 | Xtandi | $22 |
See earlier years (2024, 2022, 2021)
2024: $53
| Novartis Pharmaceuticals | Mekinist | $31 | 1 payment
|
| AstraZeneca Pharmaceuticals LP | Tagrisso | $22 | 1 payment
|
2022: $26
| Acrotech Biopharma | Beleodaq | $26 | 2 payments
|
2021: $14
| Acrotech Biopharma | Beleodaq | $14 | 1 payment
|
Professional record
- NPI
- 1487660023
- Licence
- CA G29205California G29205: Current · expires 2027-02-28
- Trained
- University of Kentucky College of Medicine, 1973
- Video visits
- Lists video visits
- Gender
- Male
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207RH0003X (207RH0003X)
- Mailing address
- 2350 W El Camino Real, 2nd Floor, Mountain View, CA, 94040
- NPI first listed
- 2006-08-01
- NPI last updated
- 2011-12-01
This is when the NPI record was last certified, not a medical board exam.